Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ImmunityBio, Inc. (NK)
|
Add to portfolio |
|
|
|
| Price: |
$16.76
| | Metrics |
| OS: |
456.2
|
M
| |
|
|
| Market cap: |
$7.65
|
B
| |
|
|
|
Net debt:
|
$685
|
M
| |
|
|
|
EV:
|
$8.33
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 0.9 | 0.6 | 2.2 | 0.0 | 0.0 | 0.0 | 0.2 | 0.6 |
| Revenue growth | 54.4% | -72.5% | 4585.1% | 4.4% | 2.3% | -81.4% | -63.2% | 6.8% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.9 | 0.6 | 2.2 | 0.0 | 0.0 | 0.0 | 0.2 | 0.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Selling, general and administrative | 135.3 | 71.3 | 46.5 | 42.7 | 57.1 | 95.4 | 227.7 | 4.6 |
| Research and development | 196.0 | 139.5 | 112.0 | 55.7 | 42.0 | 29.2 | 11.4 | 1.6 |
| EBITA | -331.1 | -210.2 | -156.3 | -96.1 | -96.8 | -121.9 | -237.6 | -5.6 |
| EBITA margin | -35447.9% | -34747.1% | -7095.9% | -204444.7% | -215155.6% | -277045.5% | -100667.8% | -869.7% |
| Amortization of intangibles | | | | 2.3 | 2.3 | 2.6 | 1.3 | |
| EBIT | -331.1 | -210.2 | -156.3 | -98.4 | -99.1 | -124.5 | -238.9 | -5.6 |
| EBIT margin | -35447.9% | -34747.1% | -7095.9% | -209338.3% | -220266.7% | -282954.5% | -101218.6% | -869.7% |
| Pre-tax income | -349.8 | -226.0 | -160.3 | -96.7 | -96.9 | -121.4 | -237.2 | -6.2 |
| Income taxes | 0.0 | -1.8 | -0.1 | -0.5 | -0.5 | -0.6 | -0.3 | 0.0 |
| Tax rate | | 0.8% | 0.1% | 0.5% | 0.5% | 0.5% | 0.1% | |
| Net income | -346.8 | -221.9 | -157.8 | -96.2 | -96.4 | -120.8 | -236.9 | -6.2 |
| Net margin | -37129.6% | -36669.6% | -7165.2% | -204736.2% | -214273.3% | -274565.9% | -100371.2% | -964.9% |
| |
| Diluted EPS | ($0.89) | ($0.59) | ($0.43) | ($1.22) | ($1.20) | ($1.47) | ($3.31) | ($0.75) |
| Shares outstanding (diluted) | 389.2 | 377.1 | 366.3 | 79.1 | 80.6 | 82.0 | 71.5 | 8.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|